Treatment of Adrenal Metastases Using Hypofractionated Stereotactic Body Radiosurgery
Purpose/Objective(s): Hypofractionated Stereotactic Body Radiosurgery (HFSR) is a non-invasive focused beam technique that delivers high dose radiation to extracranial cancers. The use of HFSR was evaluated for the treatment of adrenal metastases.
Materials/Methods: 45 patients with 49 adrenal metastases underwent HFSR during a 74 month period. 61% of the metastases were from a lung cancer origin. All the patients were evaluated prospectively before and after treatment. Age ranged from 42 to 78 years (mean 60.6) with 19 females and 26 males. 75% of patients had prior chemotherapy. Tumor volumes ranged from 2.3 to 892 cc (mean 116.35 cc). Patients were treated with 500-900 cGy (median 800) in 5-8 fractions (median 5) for a total dose of 2500-4500 cGy (median 4000). Cancers were radiographically evaluated with contrast CT and/or MRI studies and reviewed independently by radiologists. Control of the treated cancer is defined as cessation of growth, shrinkage or disappearance of the cancer after treatment.
Results: Follow up ranged from 1 to 54 months (mean 10.4). The overall control rate was 88%. For tumors <116.35cc there was an 87% control rate, and a 91% control rate for tumors ≥116.35cc. For tumors receiving <4000 cGy there was an 80% control rate compared to 93% for adrenal metastases that received ≥4000 cGy. Of the tumors treated with ≥4000 cGy, the control rate for those <116.35cc was 91%, and 100% for metastases ≥116.35. Adrenal metastases from lung cancer had an 83% control rate, while those from non-lung primaries had a 95% control rate.
Conclusions: HFSR for adrenal metastases offers a generally well-tolerated, non-invasive method with a high rate of tumor control. A larger patient group may show a dose-response analysis, as is suggested in this study. Patients will continue to be evaluated for longer follow up, possible benefits of local control and potential survival advantage. HFSR for adrenal metastases remains an option for those whom standard approaches have not produced desired results or in patients seeking an alternative to surgical or chemotherapeutic treatment.
Dr. Gil Lederman and his team have expertise in treatment of Adrenal Metastases. Hence, offering great services at RSNY in New York.







